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Introduction
Unresected Breast Cancer: Evolution of Imaging 
Findings Following Cryoablation 
Jennifer T. Bergin, M.D., Gale A. Sisney, M.D., Fred T. Lee, Jr., M.D., Elizabeth S. Burnside, 
M.D., and Lonie R. Salkowski, M.D.
Cryoablation has been used to treat both benign and malignant breast tumors. In all but one published 
case, cryoablation in breast cancer has been followed by post-procedural tumor resection. We present a 
case of an 85-year-old woman with two nonpalpable breast cancers treated with cryoablation with 18 
months of mammographic, ultrasound and histologic follow-up.
The use of freezing temperatures to kill tumors dates 
back to the 1800s when Dr. James Arnott applied salt 
and ice mixtures to breast, skin and uterine cancers. He 
observed a reduction in local hemorrhage, pain, odor, 
discharge, and tumor size [1]. The modern age of cryoab-
lation began in the 1960s when Dr. Irving S. Cooper 
developed the first closed cryoprobe that circulated cold 
nitrogen gas, allowing him to freeze the thalamus in pa-
tients with Parkinson’s Disease [2].
In the 1980s and 1990s two key developments oc-
curred, leading to an explosion in the applications of 
cryoablation. First, Dr. Gary Onik noted the echogenic 
nature of the iceball on ultrasound, leading to the first 
percutaneous cryoablation procedures. Then, in 1999, Dr. 
Fred Lee and colleagues published results of a pilot study 
using cryoablation with CT guidance [3]. They noted su-
perb visualization of the iceball, allowing precise treatment 
with minimal collateral tissue damage.
Recently, cryoablation has been used to treat both 
benign and malignant breast tumors. A multicenter trial 
using cryoablation to treat fibroadenomas in an outpatient 
setting with local anesthesia demonstrated great success. 
The procedure was safe and effective with only mild com-
plications. The median reduction in tumor volume was 
greater than 91% and patients expressed satisfaction with 
the procedure [4,5,6].
The efficacy of cryoablation in the treatment of malig-
nant breast disease is also documented in the literature 
[7,8,9,10]. The results of the first multi-institutional 
trial of cryoablation followed by resection showed that 
all tumors smaller than 1 cm in size were fully ablated. 
Tumors from 1 to 1.5 cm without an extensive extraduc-
tal component were also fully ablated. The majority of 
tumors larger than 1.5 cm were also fully ablated, though 
several demonstrated residual disease at the periphery of 
the ablation zone. Sabel et al concluded that cryoablation 
of primary breast cancer is safe and effective, but should be 
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Case Report
Figure 1. CC view from the diagnostic mammogram demon-
strates two ill-defined, spiculated masses, each smaller than 
1 cm. The 2 o’clock mass is posterior (short arrow) and the 4 
o’clock mass is anterior (long arrow).
An 85-year-old woman presented to our breast center 
with two nonpalpable masses in her right breast detected 
on screening mammogram. Subsequent diagnostic mam-
mography and sonography confirmed two masses in the 
right breast at 2 and 4 o’clock. The posterior mass at 2 
o’clock measured 7 x 6 mm while the 4 o’clock mass 
measured 6 x 6 mm. (Figures 1 and 2). Ultrasound-guided 
core biopsies and post-procedure clip placement had been 
performed of both masses at an outside institution. Pathol-
ogy showed grade 1 invasive ductal carcinoma with low 
grade DCIS in the 2 o’clock lesion and grade 2 invasive 
ductal carcinoma in the 4 o’clock lesion. The patient re-
fused surgical treatment, radiation therapy, chemotherapy, 
chemoprevention therapy, and breast MRI. She was ame-
nable to cryoablation, with the understanding that there 
was no proven benefit of cryoablation in the breast.
The patient was treated as an outpatient at our breast 
center by two radiologists (GAS, FTL) with extensive 
experience with percutaneous breast procedures and over 
12 years experience in interventional oncology procedures. 
limited to invasive carcinomas smaller than 1.5 cm with 
less than 25% DCIS on the core biopsy [9].
In all but one published case, cryoablation in breast 
cancer has been followed by post-procedural tumor resec-
tion [11]. 
Figure 2. Post-biopsy and pre-ablation sonogram demon-
strates a hypoechoic, shadowing mass at 2 o’clock with a 
central biopsy clip ( white arrow). The 4 o’clock mass had a 
similar sonographic appearance.
Informed consent was obtained. Following routine sterile 
preparation, buffered 1% lidocaine was injected subcuta-
neously for local anesthesa. The patient received 0.5 mg 
Midazolam and 50 micrograms Fentanyl for sedation. 
Two 3 mm incisions were made in the medial right breast. 
With ultrasound guidance, a 1.7 mm diameter cyroprobe 
(Endocare, Irvine, California, USA) was placed into the 
center of each mass for simultaneous treatment. The tips of 
the probes were positioned 3 mm distal to the tumors. A 
short freeze cycle was used to freeze the probes in position. 
Then, a 10-minute freeze cycle was applied followed by 
a passive 5-minute thaw and a second 10-minute freeze. 
The freeze temperatures achieved were at least -140 degrees 
centrigrade. The iceball formation was monitored continu-
ously with ultrasound. At the completion of the second 
freeze cycle, an active 10-minute thaw was initiated and 
the probes were removed. Pressure was applied to the entry 
sites for approximately 5 minutes and Band-Aids were ap-
plied. The patient was observed in the radiology recovery 
area for 2 hours prior to discharge home. She tolerated the 
procedure well with no significant pain or complication.
Both tumors were successfully cryoablated. During 
the procedure ice balls completely encased the tumors 
and approximately a 1 cm margin of adjacent tissue in all 
directions. At two hours post-ablation, the ice balls had 
resolved, leaving small indistinct areas of decreased echo-
genicity that were thought to represent the residual tumors 
and surrounding tissue at each site.
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Figure 3. 6 months after cryoablation, the diagnostic mam-
mogram CC view demonstrates similar changes at both the 2 
o’clock (short arrow) and 4 o’clock (long arrow) sites. The halo 
of density at each site is decreased compared to the immedi-
ate post-ablation appearance. At 2 o’clock, the central mass is 
no longer seen, while at 4 o’clock the central mass continues 
to decrease in size and appears less defined.
Figure 4. Sonogram at 6 months after cryoablation demon-
strates the 2 o’clock mass as a poorly defined hypoechoic 
area with a central biopsy clip ( white arrow). The halo of 
increased density noted immediately after cryoablation has 
resolved.
At six weeks post-ablation, the patient returned for 
sonography and mammography. The mammogram 
demonstated the posterior 2 o’clock lesion with a biopsy 
clip in the center of an irregular mass. A halo of soft tissue 
density surrounded the mass. Similarly, there was a biopsy 
clip in the center of the 4 o’clock mass with a surrounding 
halo of density. Sonography showed an irregular hy-
poechoic central area with an approximately 1 cm hyper-
echoic rim at each site. Biopsy clips were seen centrally in 
both lesions.
Three months after ablation, the irregular mass at 2 
o’clock was more lucent on mammography. A halo of sur-
rounding density persisted. At 4 o’clock identical changes 
were noted. Sonography showed increasingly indistinct 
borders to the hypoechoic central areas. The hyperechoic 
rims were less prominent, corresponding with the resolving 
mammographic densities at each site.
On the mammogram at six months post-ablation, the 
irregular mass at 2 o’clock was no longer seen (Figure 3). 
The halo of density was also significantly decreased. At 4 
o’clock the irregular mass was less prominent and there 
was slightly decreased surrounding density. Sonographic 
findings correlated with further interval decrease in the 
hyperechoic rims. The hypoechoic central areas decreased 
in size as well at each site (Figure 4).
Mammogramphy one year after cryoablation showed 
the biopsy clips with no definite residual mass at either site 
(Figure 5). There was minimal residual surrounding den-
sity without architectural distortion or new calcification. 
Without the aid of the biopsy clips, the lesions would have 
been difficult to locate on ultrasound. Both hyperechoic 
rims had resolved (Figure 6).
At eighteen months post-ablation, the patient returned 
for a follow-up diagnostic mammogram and sonogram. 
The biopsy clips were again noted with no residual mass at 
either site. There was no density, architectural distortion, 
or calcification at the 2 o’clock site. There was minimal 
residual surrounding density at the 4 o’clock anterior site 
with no architectural distortion or calcification. A new 8 
mm high density mass was noted at 3 o’clock, between 
the 2 o’clock and 4 o’clock sites of prior cryoablation, but 
separated from them by at least 2 cm on mammography. 
The mass demonstrated irregular margins (Figure 7).
On ultrasound, the two sites of prior cryoablation 
appeared similar to the twelve month follow-up with 
indistinct hypoechoic areas noted around the biopsy clips. 
A new mass was seen correlating with the mammographic 
findings. The mass was hypoechoic and microlobulated, 
measuring 9 mm in greatest dimension (Figure 8).
An ultrasound-guided core biopsy was recommended 
for the new mass. This was performed with a 9-gauge 
Suros vacuum assisted biopsy device. At the same time, the 
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Figure 5. CC view mammogram obtained 12 months after 
treatment shows the central masses have resolved at both 
the 2 o’clock (short arrow) and 4 o’clock (long arrow) sites. 
There is minimal surrounding density with no architectural 
distortion or calcification.
Figure 6. Sonogram at the 2 o’clock position 12 months after 
cryoablation shows the site is difficult to locate except for 
the marker clip ( white arrow). A very poorly defined area of 
decreased echogenicity is noted.
patient consented to biopsy of the prior cryoablation sites. 
At each of the two sites, the biopsy needle was placed in 
the center of the cryoablation site, guided by the marker 
clips. New marker clips were placed at each of the three 
sites and a mammogram was performed to confirm clip 
placement. The post-biopsy mammogram demonstrated 
three separate marker clips with interval removal of the 
two old clips at 2 and 4 o’clock.
Pathology of the new 3 o’clock mass demonstrated 
infiltrating ductal carcinoma (Bloom Richardson grade 1) 
with a small (0.5 mm) focus of low grade DCIS. Results 
from the 2 o’clock site of cryoablation showed benign 
breast tissue. At the 4 o’clock site a small focus (0.5 mm) 
of low grade DCIS was noted with reparative changes of 
prior biopsy.
Discussion
The post-treatment mammography and sonography 
in our patient demonstrated changes similar to those 
described in cryoablated benign breast tissue of an animal 
model and cryoablated fibroadenomas [7,12]. Mammog-
raphy showed gradual lesion resorption with decreasing 
density. Sonography revealed ill-defined central masses 
with hyperechoic rims that slowly resolved. There was 
no calcification or architectural distortion to complicate 
post-procedural image interpretation. When compared to 
surgery, the sequelae of cryoablation using mammographic 
and sonographic criteria are significantly decreased. This 
may translate into improved detection of tumor recurrence 
in breast cancers treated with cryoablation versus surgery, 
where published data demonstrates decreased sensitivity 
of mammography due to surgery and radiation-related 
changes in the breast parenchyma [13,14,15].
The occurrence of a new cancer in our patient 18 
months after initial cryoablation of two separate disease 
foci does not appear to be a failure of cryoablation. This 
new focus of disease was separated from the 2 o’clock site 
by 3 cm and from the 4 o’clock site by 2 cm on mammog-
raphy.
The presence of noncalcified DCIS in the core biopsy 
performed 18 months after cryoablation at the 2 o’clock 
site points to one of the greatest challenges facing ablative 
therapies in the breast. Existing literature regarding cryoab-
lation of breast carcinoma indicates that the presence of 
an extensive (greater than 25%) intraductal component 
should exclude the patient from percutaneous cryoablation 
[8,9,10,11]. With present imaging techniques, it may be 
difficult to identify these patients. Mammography shows 
microcalcifications forming in DCIS [16,17]. However, 
mammography is inaccurate at predicting the extent of 
disease if only a portion of the malignancy is calcified [18]. 
Sonography is similarly inaccurate at determining the pres-
Figure 8. Sonogram at the 2 o’clock position 18 months after 
cryoablation shows the biopsy clip at 2 o’clock (white arrow) 
with a poorly defined area of surrounding hypoechogenicity.
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is determination of treatment margins. The post-ablation 
core biopsy of the 2 o’clock site showed DCIS, even 
though there was no evidence of DCIS on the pre-ablation 
core biopsy. This DCIS may have been present at the time 
of initial treatment. If so, it likely would have been identi-
fied on wide excision and tumor-free margins obtained. 
Pathologic margin status is one of the most important 
predictors for local recurrence [26,27]. The use of MRI 
for ablation planning and follow-up should be helpful. At 
our instituion, following hepatic radiofrequency ablation, 
a contrast enhanced CT is performed immediately after 
the ablation session to evaluate for residual enhancement. 
If enhancement persists at the margins, there is presumed 
residual tumor and additional ablation is performed, 
typically within the same ablation session. A similar 
strategy could be applied to cryoablation in the breast 
with evaluation for residual gadolinium enhancement on 
MRI. Furthermore, MR guidance may prove to be a more 
accurate imaging modality for monitoring and guidance of 
cryoablation. Tumor and frozen tissue are well differenti-
ated on MRI and MRI provides delineation of the iceball 
in three-dimensions, an advantage over ultrasound [28].
Several thermal ablation techniques are currently under 
evaluation for use in the breast. A discussion of all the 
different ablative modalities is beyond the scope of this 
case report. However, cryoablation is unique in its use of 
hypothermia. While hyperthermic ablative processes dena-
Figure 7. 18 months after cryoablation, the 2 o’clock (short 
arrow) and 4 o’clock (long arrow) sites are unchanged in ap-
pearance with no residual or recurrent mass at either site. A 
new 8 mm mass is present at 3 o’clock (circle).
ence and extent of an intraductal component [19].
Overall, the results regarding MRI in the evaluation of 
DCIS have been modest, with published series showing 
MRI sensitivities for DCIS as low as 40% and as high as 
100% [20,21,22,23,24]. MRI does not dependably show 
the classic microcalcifications that form in DCIS and 
DCIS may show delayed or even no contrast enhance-
ment on MRI [18,20]. Thus, the addition of MRI to the 
evaluation of potential cryoablation patients is useful, but 
somewhat limited in its sensitivity for DCIS.
The tumors in our case were easily encompassed with 
the iceballs generated by the 1.7 mm probes used, with 
ultrasound demonstrating an approximate 1 cm margin 
of ablated tissue in all directions around the tumors. 
Published series suggest a size limitation of 1.5 cm, with 
incomplete ablation occuring in larger tumors [8,10]. This 
limitation is largely due to the type of cryoprobe used. All 
published cases to date report the use of single probes. A 
single 1.7 mm probe produces an iceball approximately 3 
cm in diameter. If positioned centrally in a 1 cm tumor, 
the single probe would ablate the tumor and provide mar-
gins of approximately 1 cm. Elsewhere in the body and in 
fibroadenomas, multiple probes have been used in a single 
lesion with success [5,25]. With proper probe placement, 
a multi-probe technique could be similarly successful in 
breast malignancies.
Another challenge facing in situ breast cancer ablation 
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